4 results on '"Darbyshire, JH"'
Search Results
2. The AIDS incubation period in the UK estimated from a national register of HIV seroconverters
- Author
-
Beral, V, Babiker, A, Brettle, R, Carne, C, Darbyshire, JH, Evans, BG, Gill, ON, Gilson, RJC, Goldberg, D, Hawkins, DA, Jeffries, D, Johnson, AM, Johnson, MA, Mcmichael, AJ, Mortimer, PP, Phillips, AN, Porter, K, Pozniak, A, Weber, J, Wellsteed, S, and Comm, UKRHIVSS
- Published
- 2016
3. Effect of ignoring the time of HIV seroconversion in estimating changes in survival over calendar time in observational studies: results from CASCADE
- Author
-
Porter, K, Babiker, A, Walker, S, Darbyshire, J, Gill, N, Beral, V, Coutinho, R, Lee, C, Meyer, L, Rezza, G, Tyrer, F, Dabis, F, Marimoutou, C, Boufassa, F, Hamouda, O, Brunn, M, Pezzotti, P, Lorenzo, JI, Touloumi, G, Hatzakis, A, Karafoulidou, A, Katsarou, O, Brettle, R, Del Amo, J, del Romero, J, Prins, M, Coutinho, RA, van Benthem, B, Kirk, O, Pedersen, C, AGuado, IH, Perez-Hoyos, S, Eskild, A, Bruun, JN, Sannes, M, Sabin, C, Johnson, AM, Phillips, AN, Darbyshire, JH, Egger, M, Francioli, P, Rickenbach, M, Cooper, D, Kaldor, J, Vizzard, J, Tusell, JM, Ruiz, I, Cayla, JA, de Olalla, PG, Day, NE, De Angelis, D, Collaboration, CASCADE, Infectious diseases, APH - Global Health, AII - Inflammatory diseases, AII - Infectious diseases, and Medical Microbiology and Infection Prevention
- Subjects
Adult ,Male ,Pediatrics ,medicine.medical_specialty ,HIV seroconversion ,Time Factors ,Survival ,Adolescent ,Immunology ,Human immunodeficiency virus (HIV) ,HIV Infections ,Cubic Millimeter ,HIV Antibodies ,medicine.disease_cause ,Risk Assessment ,Cohort Studies ,Prevalent ,Acquired immunodeficiency syndrome (AIDS) ,Bias ,HIV Seropositivity ,medicine ,Prevalence ,Immunology and Allergy ,Humans ,business.industry ,Disease progression ,Cohort ,HIV ,Middle Aged ,medicine.disease ,CD4 Lymphocyte Count ,Seroconverters ,Infectious Diseases ,Observational study ,Female ,business ,Calendar time - Abstract
Objective: To compare estimates of changes in HIV survival over time derived from seroconverter and prevalent cohorts. Design and methods: Using pooled data from 19 seroconverter cohorts (CASCADE), the relative risk of death from HIV seroconversion by calendar time at risk from 1 January 1991 was examined. The analyses were repeated, ignoring knowledge of the time of seroconversion, but adjusting for the CD4 cell count at the time the participant came under observation, thus mimicking a prevalent cohort. Estimates from the 'prevalent' cohort approach were compared with those obtained from the sero-converter cohort. Results: Of 5428 subjects at risk on 1 January 1991 or later, 1312 (24.2%) had died. In the analysis based on time from seroconversion, estimates of the effect of calendar year showed marked reductions in mortality in 1997-1999 only, with no evidence of a linear trend over the period 1991-1996 (P-trend = 0.85). Using the prevalent cohort approach a decrease in the relative risk of death was observed from 1991 to 1998-1999, with a statistically significant trend of a decrease in risk from 1991 to 1996 (P-trend = 0.002). Similar findings were observed when the analyses was repeated taking the start date of the cohort as 1 January 1988. Conclusion: Lack of knowledge of HIV infection duration may lead to biased and exaggerated estimates of survival improvements over time. The adjustment for duration of infection in prevalent HIV cohorts through laboratory markers may compensate inadequately for this. (C) 2000 Lippincott Williams and Wilkins.
- Published
- 2016
- Full Text
- View/download PDF
4. Neurocognition and quality of life after reinitiating antiretroviral therapy in children randomized to planned treatment interruption
- Author
-
Ananworanich, J, Melvin, D, Amador, Jt, Childs, T, Medin, G, Boscolo, V, Compagnucci, A, Kanjanavanit, S, Montero, S, Gibb, Dm, PENTA 11 Study Group including Aboulker, J, Babiker, A, Belfrage, E, Bernardi, S, Bologna, R, Burger, D, Butler, K, Castelli Gattinara, G, Castro, H, Clayden, P, Cressey, T, Darbyshire, Jh, Debré, M, de Groot, R, della Negra, M, di Biagio, A, De Rossi, A, Duicelescu, D, Faye, A, Giaquinto, C, Giacomet, V, Grosch Wörner, I, Hainault, M, Klein, N, Lallemant, M, Levy, J, Lyall, H, Marczynska, M, Marques, L, Mardarescu, M, Mellado Peña MJ, Nadal, D, Nastouli, E, Naver, L, Niehues, T, Peckham, C, Pillay, D, Popieska, J, Ramos Amador JT, Rojo Conejo, P, Rosado, L, Rosso, R, Rudin, C, Scherpbier, Hj, Sharland, M, Stevanovic, M, Thorne, C, Tovo, Pier Angelo, Tudor Williams, G, Turkova, A, Valerius, N, Volokha, A, Walker, As, Welch, S, Wintergerst, U, Aboulker, Jp, Burger, Dm, Green, H, Harper, L, Mofenson, L, Moye, J, Saïdi, Y, Cressey, Tr, Jacqz Aigrain, E, Khoo, S, Regazzi, M, Tréluyer, Jm, Ngo Giang Huong, N, Muñoz Fernandez MA, Hill, C, Lepage, P, Pozniak, A, Vella, S, Chêne, G, Vesikari, T, Hadjou, G, Léonardo, S, Riault, Y, Bleier, J, Buck, L, Duong, T, Farrelly, L, Forcat, S, Harrison, L, Horton, J, Johnson, D, Taylor, C, Chalermpantmetagul, S, Peongjakta, R, Khamjakkaew, W, Than in at, K, Chailert, S, Jourdain, G, Le Coeur, S, Floret, D, Costanzo, P, Le Thi TT, Monpoux, F, Mellul, S, Caranta, I, Boudjoudi, N, Firtion, G, Denon, M, Charlemaine, E, Picard, F, Hellier, E, Heuninck, C, Damond, F, Alexandre, G, Tricoire, J, Antras, M, Lachendowier, C, Nicot, F, Krivine, A, Rivaux, D, Notheis, G, Strotmann, G, Schlieben, S, Rampon, O, Zanchetta, M, Ginocchio, F, Viscoli, C, Martino, A, Pontrelli, G, Baldassar, S, Concato, C, Mazza, A, Rossetti, G, Dobosz, S, Oldakowska, A, Popielska, J, Kaflik, M, Stanczak, J, Stanczack, G, Dyda, T, Kruk, M, González Tomé MI, Delgado García, R, Fernandez Gonzalez MT, Mellado Peña, M, Martín Fontelos, P, Garcia Mellado MI, Medina, Af, Ascencion, B, Garcia Bermejo, I, Navarro Gomez DM, Saavedra, J, Prieto, C, Jimenez, Jl, Garcia Torre, A, de José Gómez MI, García Rodriguez MC, Moreno Pérez, D, Núñez Cuadros, E, Asensi Botet, F, Otero Reigada, C, Pérez Tamarit MD, Vilalta, R, Molina Moreno JM, Rainer, T, Schupbach, J, Rutishauser, M, Bunupuradah, T, Butterworth, O, Phasomsap, C, Prasitsuebsai, W, Chuanjaroen, T, Jupimai, T, Ubolyam, S, Phanuphak, P, Puthanakit, T, Pancharoen, C, Mai, C, Namwong, T, Punsakoon, W, Payakachat, S, Chutima, D, Raksasang, M, Foster, C, Hamadache, D, Campbell, S, Newbould, C, Monrose, C, Abdulla, A, Walley, A, Patel, D, Kaye, S, Seery, P, Rankin, A, Wildfire, A, Novelli, V, Shingadia, D, Moshal, K, Flynn, J, Clapson, M, Allen, A, Spencer, L, Rackstraw, C, Ward, B, Parkes, K, Depala, M, Jacobsen, M, Poulsom, H, Barkley, L, Miah, J, Lurie, P, Keane, C, Mcmaster, P, Phipps, M, Orendi, J, Farmer, C, Liebeschuetz, S, Sodeinde, O, Wong, S, Bostock, V, Heath, Y, Scott, S, Gandhi, K, Lewis, P, Daglish, J, Miles, K, Summerhill, L, Subramaniam, B, Weiner, L, Famiglietti, M, Rana, S, Yu, P, Roa, J, Puga, A, Haerry, A., AII - Amsterdam institute for Infection and Immunity, Paediatric Infectious Diseases / Rheumatology / Immunology, and Global Health
- Subjects
0301 basic medicine ,Male ,Pediatrics ,medicine.medical_specialty ,antiretroviral therapy ,children ,HIV ,neurocognition ,neurodevelopment ,quality of life ,treatment interruption ,Immunology and Allergy ,Immunology ,Infectious Diseases ,Adolescent ,lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4] ,Antiretroviral Therapy ,HIV Infections ,Standard score ,03 medical and health sciences ,0302 clinical medicine ,Cognition ,Acquired immunodeficiency syndrome (AIDS) ,Antiretroviral Therapy, Highly Active ,Memory span ,Medicine ,Humans ,Highly Active ,030212 general & internal medicine ,Child ,Wechsler Intelligence Scale for Children ,business.industry ,Wechsler Adult Intelligence Scale ,medicine.disease ,030112 virology ,lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] ,Treatment Outcome ,Anti-Retroviral Agents ,Test score ,Mann–Whitney U test ,Quality of Life ,Female ,business ,Neurocognitive - Abstract
Item does not contain fulltext OBJECTIVE: Understanding the effects of antiretroviral treatment (ART) interruption on neurocognition and quality of life (QoL) are important for managing unplanned interruptions and planned interruptions in HIV cure research. DESIGN: Children previously randomized to continuous (continuous ART, n = 41) vs. planned treatment interruption (PTI, n = 47) in the Pediatric European Network for Treatment of AIDS (PENTA) 11 study were enrolled. At study end, PTI children resumed ART. At 1 and 2 years following study end, children were assessed by the coding, symbol search and digit span subtests of Wechsler Intelligence Scale for Children (6-16 years old) or Wechsler Adult Intelligence Scale (>/=17 years old) and by Pediatrics QoL questionnaires for physical and psychological QoL. Transformed scaled scores for neurocognition and mean standardized scores for QoL were compared between arms by t-test and Mann-Whitney U test, respectively. Scores indicating clinical concern were compared (
- Published
- 2016
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.